OrbiMed’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
– Sell
-266,400
Closed -$30.8M – 142
2023
Q3
$30.8M Sell
266,400
-50,000
-16% -$5.37M 0.65% 56
2023
Q2
$32.5M Buy
316,400
+116,400
+58% +$12.3M 0.59% 55
2023
Q1
$21.8M Buy
200,000
+29,000
+17% +$3.21M 0.43% 63
2022
Q4
$19.5M Buy
+171,000
New +$14.2M 0.37% 65
2022
Q3
– Sell
-2,108,555
Closed -$168M – 156
2022
Q2
$168M Sell
2,108,555
-88,000
-4% -$8.33M 3.05% 4
2022
Q1
$231M Sell
2,196,555
-303,500
-12% -$29.6M 3.75% 2
2021
Q4
$269M Sell
2,500,055
-110,300
-4% -$12M 3.46% 3
2021
Q3
$286M Sell
2,610,355
-311,800
-11% -$32.4M 3.14% 3
2021
Q2
$274M Sell
2,922,155
-222,200
-7% -$20.4M 2.77% 7
2021
Q1
$289M Buy
3,144,355
+135,600
+5% +$11.4M 2.71% 6
2020
Q4
$220M Hold
3,008,755
– – 1.93% 12
2020
Q3
$234M Buy
3,008,755
+140,845
+5% +$9.69M 2.94% 6
2020
Q2
$159M Buy
2,867,910
+526,210
+22% +$22.5M 2.24% 15
2020
Q1
$69.4M Buy
2,341,700
+759,400
+48% +$25.7M 1.17% 31
2019
Q4
$57.3M Buy
+1,582,300
New +$48.5M 0.82% 40
2015
Q4
– Sell
-204,000
Closed -$4.04M – 136
2015
Q3
$4.04M Sell
204,000
-747,000
-79% -$23.6M 0.04% 111
2015
Q2
$33M Sell
951,000
-124,000
-12% -$3.78M 0.28% 67
2015
Q1
$27.9M Hold
1,075,000
– – 0.24% 67
2014
Q4
$13.9M Buy
1,075,000
+179,000
+20% +$2.24M 0.13% 89
2014
Q3
$11M Buy
896,000
+350,000
+64% +$4.07M 0.11% 95
2014
Q2
$8.64M Buy
546,000
+350,000
+179% +$5M 0.1% 94
2014
Q1
$2.96M Buy
+196,000
New +$2.21M 0.04% 129

Other funds holding HZNP

OrbiMed's HZNP Position: Q4 2023 in Review

OrbiMed sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 266,400 shares — an estimated $30.8M sold.

OrbiMed first reported a position in HZNP in Q1 2014 and held it in 22 quarters. The position peaked at $289M in Q1 2021. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • OrbiMed reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • OrbiMed sold 266,400 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $30.8M.
  • OrbiMed first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2014 and held it in 22 quarters.
  • OrbiMed's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $289M in Q1 2021.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on OrbiMed's 13F filing for Q4 2023, filed 14 Feb 2024.